Media Coverage

Quest Diagnostics has struck a deal to use healthcare software firm Epic Systems' suite of enterprise laboratory software and services, the companies said on Tuesday. Under the agreement, Epic's enterprise offerings — including its Aura specialty lab data exchange system, its Beaker lab information system, and its MyChart patient health record portal — will be implemented across Quest's national lab operations.

The collaboration will allow wearable device users to order clinical tests, schedule appointments, and receive results through the WHOOP mobile application. WHOOP announced that Quest Diagnostics will serve as the US lab provider for WHOOP Advanced Labs, a new feature that will integrate clinical laboratory testing into the wearable device company’s mobile application.

Quest Diagnostics-owned liquid biopsy developer Haystack Oncology is expecting in the next year to bring a new wealth of data supporting the ability of its circulating tumor DNA technology for use in minimal/molecular residual disease (MRD) detection across a variety of indications, especially those where its higher sensitivity may give it a boost over other technologies.

The relationship between Quest Diagnostics and Hackensack Meridian Health is taking another test. For the last four years, the Secaucus-based lab services provider has managed laboratory operations and performed reference testing for 11 hospitals in the Edison-headquartered health care network. Quest recently deepened that collaboration by opening its 250,000-square-foot next-generation flagship laboratory in Clifton to give students at Hackensack Meridian Health’s School of Medicine a behind-the-scenes look at clinical lab work.

Quest Diagnostics has launched a pharmacogenomic (PGx) laboratory test service designed to help healthcare providers understand individual genetic responses to select drug therapies and optimize medication selection and dosing decisions.

New research by Quest Diagnostics suggests that more and more U.S. workers are using the powerful synthetic opioid drug fentanyl, since it’s showing up in random drug tests carried out in workplaces across the country. This bleak news might not be too surprising, given the dramatic speed with which the drug has affected a population that remains plagued by opioid addiction.

Quest Diagnostics has introduced a new pharmacogenomic (PGx) laboratory testing service designed to assist healthcare providers in understanding their patients’ genetic responses to specific medications. This service is intended to support clinicians in selecting appropriate drugs and determining optimal dosages.

More Americans are testing positive for fentanyl use in randomized workplace drug tests, highlighting a persistent challenge for employers. The positive rate for urine tests indicating the presence of the synthetic opioid fentanyl was 1.13% in 2024. That is up from 0.91% in 2023 and double the rate in 2020, according to a recent analysis of more than eight million drug tests by Quest Diagnostics, one of the U.S.’s largest drug-testing labs.

Jeff Lusby is the general manager of healthcare IT solutions at Quest Diagnostics. With more than 29 years in healthcare IT, Lusby has extensive experience with technology implementations, from the sales journey to installation, support and account management. In his current role, he leads Quest’s Quanum Enterprise Content Solutions software business.

Corewell Health has signed on to a joint venture with Quest Diagnostics covering inpatient and outpatient lab management and the construction of a new 100,000-square-foot advanced lab facility.